PR Newswire
DUBLIN, Sept. 19, 2016
DUBLIN, Sept. 19, 2016 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that its wholly owned subsidiary, Shire Acquisitions Investments Ireland Designated Activity Company ("SAIIDAC"), priced its inaugural public offering of $12.1 billion aggregate principal amount of senior notes. The offering consists of four series of senior notes:
$3.3 billion 1.900% Senior Notes due 2019;
$3.3 billion 2.400% Senior Notes due 2021;
$2.5 billion 2.875% Senior Notes due 2023; and
$3.0 billion 3.200% Senior Notes due 2026
The notes are expected to be issued on September 23, 2016, subject to customary closing conditions. Shire intends to use the net proceeds to fully repay amounts outstanding under its January 2016 bridge facilities agreement, which were used to finance its acquisition of Baxalta Incorporated ("Baxalta"), and for general corporate purposes.
The offering is being made only by means of a base prospectus and related prospectus supplement. Copies of the base prospectus and final prospectus supplement, when it becomes available, may be obtained by contacting:
An effective registration statement is on file with the U.S. Securities and Exchange Commission ("SEC"), and a copy of the base prospectus and related prospectus supplement will also be available on the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
For further information please contact:
Investor Relations | | |
Sarah Elton-Farr | +44 1256 894157 | |
Ian Karp | +1 781 482 9018 | |
Robert Coates | +44 1256 894874 | |
Media | | |
Gwen Fisher | +1 484 595 9836 | |
Debbi Ford | +1 617 949 9083 |
NOTES TO EDITORS
Stephen Williams, Deputy Company Secretary (responsible for arranging the release of this announcement)
Inside Information
This announcement contains inside information.
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
Forward-Looking Statements
Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:
All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shire-prices-public-offering-of-senior-notes-300330533.html
SOURCE Shire plc
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.